2025 Update on Lipids

Dyslipidemia: Causes, Diagnosis, and Modern Management

Dyslipidemia refers to abnormal levels of lipids in the blood, including cholesterol and triglycerides. It is one of the most important—and modifiable—risk factors for atherosclerosis, coronary artery disease, stroke, and peripheral vascular disease. With cardiovascular disease rising globally, understanding dyslipidemia is essential for prevention and early intervention.

What Exactly Is Dyslipidemia?

Dyslipidemia occurs when the balance of blood lipids is disrupted. The common patterns include:

High LDL cholesterol (“bad cholesterol”)

Low HDL cholesterol (“good cholesterol”)

High triglycerides

Mixed dyslipidemia (a combination of abnormalities)

These lipid abnormalities accelerate plaque formation in arteries, leading to progressive narrowing and potential plaque rupture.

---

Causes of Dyslipidemia

1. Primary (Genetic) Causes

Inherited disorders can significantly raise lipid levels, such as:

Familial hypercholesterolemia (FH)

Familial combined hyperlipidemia

Familial dysbetalipoproteinemia

These conditions usually present at a younger age and cause severe elevations of LDL or triglycerides.

2. Secondary Causes

Common and often reversible:

Diabetes mellitus

Hypothyroidism

Chronic kidney disease

Obesity and metabolic syndrome

Excessive alcohol intake

High-carbohydrate diet

Medications (beta-blockers, steroids, thiazides, oral estrogens, antipsychotics)

---

How Dyslipidemia Is Diagnosed

Diagnosis begins with a fasting or non-fasting lipid panel:

Lipid Parameter Optimal Value

LDL-C <100 mg/dL (lower for high-risk groups)

HDL-C >40 mg/dL (men), >50 mg/dL (women)

Triglycerides <150 mg/dL

Total Cholesterol <200 mg/dL

Special Tests (when needed)

Apolipoprotein B (ApoB)

Lipoprotein(a) [Lp(a)]

Non-HDL cholesterol

Coronary artery calcium score (to refine risk)

---

Who Should Be Screened?

All adults ≥20 years at least once every 5 years

Earlier screening for those with:

Obesity

Diabetes

Strong family history of premature heart disease

Smoking

Chronic diseases (CKD, HIV)

---

Clinical Symptoms

Most patients have no symptoms.

Clues for severe or genetic dyslipidemia include:

Xanthomas (tendon or tuberous)

Corneal arcus (in young patients)

Pancreatitis (from very high triglycerides)

---

Dyslipidemia and Cardiovascular Risk

High LDL and high triglycerides both contribute to plaque formation, but LDL cholesterol remains the primary target in all major guidelines.

Lowering LDL reduces:

Heart attacks

Stroke

Mortality

Need for stent or bypass surgery

---

Management of Dyslipidemia

Management depends on the patient’s cardiovascular risk.

1. Lifestyle Modifications (First Step for All Patients)

Diet:

Reduce saturated fats, trans fats

Increase fiber intake

Add omega-3–rich foods (fish, flaxseed)

Exercise:

At least 150 min/week of moderate activity

Weight loss:

Even 5–10% reduction improves lipid levels

Quit smoking & limit alcohol

---

2. Medications

a. Statins (First-line therapy)

Most effective at lowering LDL and preventing cardiovascular events.

Examples:

Atorvastatin

Rosuvastatin

Simvastatin

b. Ezetimibe

Used when LDL goal is not met on statins.

c. PCSK9 Inhibitors

For high-risk patients or genetic hypercholesterolemia.

d. Fibrates

Best for lowering triglycerides, especially >500 mg/dL.

e. Omega-3 Fatty Acids

Helpful for triglyceride lowering.

f. Niacin

Rarely used now due to side effects.

---

LDL Target Goals (General Guide)

Patient Category LDL Goal

Low risk <130 mg/dL

Moderate risk <100 mg/dL

High risk (diabetes, CKD) <70 mg/dL

Very high risk (post-MI, multiple events) <55 mg/dL

---

Complications of Untreated Dyslipidemia

Myocardial infarction

Stroke

Peripheral artery disease

Sudden cardiac death

Pancreatitis (from very high triglycerides)

---

Key Takeaways

Dyslipidemia is silent but dangerous—screening is essential.

LDL cholesterol is the main target for therapy.

Lifestyle changes remain foundational.

Statins are the most effective and evidence-based therapy.

Advanced therapies (ezetimibe, PCSK9 inhibitors) help achieve aggressive LDL goals in high-risk patients.